ALKERMES | ALKS - Current Liabilities


ALKERMES reported $474.36M in Current Liabilities for its fiscal quarter ending in September of 2025.





Current Liabilities Change Date
AbbVie USD 43.29B 3.9B Dec/2025
Acadia Pharmaceuticals USD 356.58M 26.56M Sep/2025
ALKERMES USD 474.36M 31.6M Sep/2025
Amgen USD 25.49B 3.7B Dec/2025
Biogen USD 3.35B 59.4M Dec/2025
BioMarin Pharmaceutical USD 798.44M 114.19M Sep/2025
Bristol-Myers Squibb USD 28.14B 608M Sep/2025
Coherus Biosciences USD 372.3M 108.67M Sep/2025
Eli Lilly USD 35.23B 4.91B Dec/2025
Gilead Sciences USD 11.81B 485M Dec/2025
Heron Therapeutics USD 89.71M 168.89M Sep/2025
Ionis Pharmaceuticals USD 903.46M 6.22M Sep/2025
J&J USD 54.13B 3.26B Dec/2025
Malin Corporation EUR 1000K 500K Dec/2024
Merck USD 28.63B 2.59B Sep/2025
Minerva Neurosciences USD 2.67M 143K Sep/2025
Nektar Therapeutics USD 66.34M 5.05M Sep/2025
Neurocrine Biosciences USD 743.4M 105.4M Dec/2025
Otsuka Holdings JPY 749.11B 50.84B Dec/2025
Ovoca Bio EUR 2.44M 1.1M Jun/2022
Pfizer USD 36.6B 1.13B Sep/2025
Regeneron Pharmaceuticals USD 4.37B 56.7M Dec/2025
Vertex Pharmaceuticals USD 3.86B 614.1M Dec/2025